Anti-CD19/4-1BB/CD3ζ CAR T
/ University of Alberta
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 10, 2026
ACIT001/EXC002: Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
(clinicaltrials.gov)
- P1/2 | N=63 | Recruiting | Sponsor: University of Alberta | Trial primary completion date: Dec 2025 ➔ Dec 2026
Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics
1 to 1
Of
1
Go to page
1